Shi X - Search Results

1

Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.

Duan Y, Yu T, Jin L, Zhang S, Shi X, Zhang Y, Zhou N, Xu Y, Lu W, Zhou H, Zhu H, Bai S, Hu K, Guan Y. Duan Y, et al. Among authors: shi x. Eur J Med Chem. 2023 Jun 5;254:115367. doi: 10.1016/j.ejmech.2023.115367. Epub 2023 Apr 14. Eur J Med Chem. 2023. PMID: 37086699

2

Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents.

Duan YC, Ma YC, Zhang E, Shi XJ, Wang MM, Ye XW, Liu HM. Duan YC, et al. Eur J Med Chem. 2013 Apr;62:11-9. doi: 10.1016/j.ejmech.2012.12.046. Epub 2013 Jan 4. Eur J Med Chem. 2013. PMID: 23353743

3

Efficient construction of novel D-ring modified steroidal dienamides and their cytotoxic activities.

Yu B, Shi XJ, Ren JL, Sun XN, Qi PP, Fang Y, Ye XW, Wang MM, Wang JW, Zhang E, Yu DQ, Liu HM. Yu B, et al. Eur J Med Chem. 2013 Aug;66:171-9. doi: 10.1016/j.ejmech.2013.05.035. Epub 2013 Jun 5. Eur J Med Chem. 2013. PMID: 23792764

4

A novel [1,2,4] triazolo [1,5-a] pyrimidine-based phenyl-linked steroid dimer: synthesis and its cytotoxic activity.

Yu B, Shi XJ, Zheng YF, Fang Y, Zhang E, Yu DQ, Liu HM. Yu B, et al. Eur J Med Chem. 2013 Nov;69:323-30. doi: 10.1016/j.ejmech.2013.08.029. Epub 2013 Sep 4. Eur J Med Chem. 2013. PMID: 24077182

5

Synthesis and preliminary biological evaluation of 1,2,3-triazole-Jaspine B hybrids as potential cytotoxic agents.

Xu JM, Zhang E, Shi XJ, Wang YC, Yu B, Jiao WW, Guo YZ, Liu HM. Xu JM, et al. Eur J Med Chem. 2014 Jun 10;80:593-604. doi: 10.1016/j.ejmech.2014.03.022. Epub 2014 Mar 25. Eur J Med Chem. 2014. PMID: 24835817

6

Discovery of tofacitinib derivatives as orally active antitumor agents based on the scaffold hybridization strategy.

Shi XJ, Wang S, Li XJ, Yuan XH, Cao LJ, Yu B, Liu HM. Shi XJ, et al. Eur J Med Chem. 2020 Oct 1;203:112601. doi: 10.1016/j.ejmech.2020.112601. Epub 2020 Jul 12. Eur J Med Chem. 2020. PMID: 32682202

7

Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy.

Duan YC, Zhang SJ, Shi XJ, Jin LF, Yu T, Song Y, Guan YY. Duan YC, et al. Eur J Med Chem. 2021 Oct 15;222:113588. doi: 10.1016/j.ejmech.2021.113588. Epub 2021 Jun 1. Eur J Med Chem. 2021. PMID: 34107385 Review.

8

Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer.

Song Z, Gao K, Asmamaw MD, Liu YJ, Zheng YC, Shi XJ, Liu HM. Song Z, et al. Eur J Pharmacol. 2022 Feb 5;916:174725. doi: 10.1016/j.ejphar.2021.174725. Epub 2021 Dec 23. Eur J Pharmacol. 2022. PMID: 34953802

9

Discovery of Novel 1,3-Diphenylpyrazine Derivatives as Potent S-Phase Kinase-Associated Protein 2 (Skp2) Inhibitors for the Treatment of Cancer.

Zhang K, Hu K, Li Q, Li M, Gao K, Yang K, Zhao B, Shi XJ, Zhang L, Liu HM. Zhang K, et al. J Med Chem. 2023 Jun 8;66(11):7221-7242. doi: 10.1021/acs.jmedchem.2c01675. Epub 2023 May 19. J Med Chem. 2023. PMID: 37204466

10

Discovery of Novel [1,2,4]Triazolo[1,5-a]pyrimidine Derivatives as Novel Potent S-Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer.

Hu K, Luo Y, Miao P, Zhao L, Zhao B, Shi XJ, Liu HM. Hu K, et al. J Med Chem. 2024 Sep 26;67(18):16435-16454. doi: 10.1021/acs.jmedchem.4c01283. Epub 2024 Sep 16. J Med Chem. 2024. PMID: 39285177

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20,650 results

Search Page

Filters